D.E. Shaw & Co
SAGE

D.E. Shaw & Co’s Sage Therapeutics SAGE Stock Holding History

D.E. Shaw & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$568K – 5196
2021
Q2 		$568K Buy
+10,000
New +$707K ﹤0.01% 3970
2020
Q3 		– Sell
-25,000
Closed -$1.04M – 4116
2020
Q2 		$1.04M Buy
+25,000
New +$907K ﹤0.01% 2900
2020
Q1 		– Sell
-70,300
Closed -$5.08M – 4210
2019
Q4 		$5.08M Hold
70,300
– – 0.01% 1724
2019
Q3 		$9.86M Hold
70,300
– – 0.01% 1171
2019
Q2 		$12.9M Hold
70,300
– – 0.02% 996
2019
Q1 		$11.2M Sell
70,300
-30,000
-30% -$4.34M 0.01% 1038
2018
Q4 		$9.61M Buy
100,300
+5,000
+5% +$572K 0.01% 1114
2018
Q3 		$13.5M Hold
95,300
– – 0.02% 954
2018
Q2 		$14.9M Buy
95,300
+50,300
+112% +$7.9M 0.02% 879
2018
Q1 		$7.25M Buy
45,000
+15,000
+50% +$2.55M 0.01% 1184
2017
Q4 		$4.94M Hold
30,000
– – 0.01% 1501
2017
Q3 		$1.87M Buy
30,000
+20,000
+200% +$1.57M ﹤0.01% 2083
2017
Q2 		$796K Buy
+10,000
New +$723K ﹤0.01% 2550

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's SAGE Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,917,284 shares — an estimated $17.5M sold.

D.E. Shaw & Co first reported a position in SAGE in Q4 2015 and held it in 34 quarters. The position peaked at $190M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,917,284 Sage Therapeutics shares in Q3 2025, an estimated $17.5M.
  • D.E. Shaw & Co first reported a position in Sage Therapeutics in Q4 2015 and held it in 34 quarters.
  • D.E. Shaw & Co's Sage Therapeutics position peaked at $190M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.